Actively Recruiting
Comparing a Standard Prostate Biopsy System With a New Needle Device Using Pathology and Computational Analysis to Measure Tissue Quality and Cancer Features
Led by Uro-1 Medical · Updated on 2026-09-04
200
Participants Needed
3
Research Sites
5 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new biopsy needle system compared to the standard of care system for prostate cancer screening. The study focuses on comparing the quality and quantity of prostate tissue samples collected by both systems. It also aims to analyze the tissue using computational pathology algorithms to assess features like atypical small acinar proliferation, Gleason scores, tissue area, length, and tortuosity, while pathologists remain blinded to the biopsy system used. Participants undergo prostate biopsy where one lobe is sampled using the standard biopsy needle and the other lobe using the novel biopsy needle system. The study compares tissue quality, diagnostic ambiguity, and morphometric parameters between these two biopsy devices. Tissue analyses occur shortly after the biopsy procedure. During the study, participants are assessed for tissue characteristics through pathology reviews within a few days after biopsy. The primary outcomes include measurements of atypical small acinar proliferation, Gleason scores, tissue area, length, and tortuosity, evaluated from enrollment through treatment and pathology review. Secondary outcomes compare standard pathology results with computational pathology findings. The study completion spans from enrollment to about two days post-treatment.
CONDITIONS
Brief Title
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
Research Team
T
Thomas Lawson, PhD
T
Ted Belleza, BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here